In a recent conversation, tech entrepreneur and longevity enthusiast Bryan Johnson gave warning about one of the wellness industry’s hottest trends: peptides.
While Johnson acknowledges that peptides can be powerful tools, he’s concerned about the growing number of people using them without understanding the full picture.
“Generally, peptides are fantastic. They are d**gs, d**g equivalents. They have d**g-like effect sizes,” he explained in an interview. However, he quickly added a crucial caveat that many enthusiasts overlook.
The peptide phenomenon has reached fever pitch, particularly in health-conscious circles. From semaglutide to various experimental compounds, these molecules have become ubiquitous among those seeking rapid improvements in body composition, metabolism, and overall wellness.
In San Francisco tech circles, the trend has become so prevalent it’s spawned its own cultural meme around Chinese peptide suppliers.
Yet Johnson draws a sharp distinction between peptides that have undergone rigorous testing and the long tail of compounds flooding the market.
“Some peptides have done the clinical work, like semaglutide,” he noted. “But then there’s a whole bunch of other class of peptides that we have no human data on.”
The lack of clinical data on many popular peptides represents a fundamental gap in knowledge that Johnson finds troubling. When pharma companies develop traditional medications, they must document not just the benefits but every potential side effect through extensive trials.
“When you hear about a d**g that does blood pressure control, you hear all the benefits, and then you hear, like in the commercial, you hear, like, this may cause d**th or kidney damage. You hear all the side effects because it’s been well characterized,” Johnson explained.
The peptide market operates differently. “With peptides, you don’t know. It’s like your bro buddy’s like, it does this amazing thing. And the whole supply chain is incentivized to only mention the benefits,” he said. Users receive enthusiastic recommendations highlighting positive outcomes while the potential downsides remain unspoken and unexplored.
This information asymmetry creates what Johnson considers one of the most dangerous scenarios in health optimization.
“If you’re doing it, proceed with caution because they’re not characterized. We don’t know,” he warned. “It’s not to say they couldn’t have benefits. It’s that you don’t know, and that’s the worst thing in health is the blind spots.”
The warning comes from someone who practices what he preaches about careful evaluation. Despite recent research published in JAMA showing that moderate coffee consumption reduces dementia risk by 18%, Johnson publicly stated he still avoids caffeine.
The 40-year study of over 130,000 participants found that 2-3 cups of caffeinated coffee daily provided significant cognitive protection, with researchers documenting 11,033 dementia cases over 43 years of follow-up.
The research distinguished between caffeinated and decaffeinated varieties, finding that only caffeinated coffee showed meaningful cognitive benefits. The neuroprotective effects likely stem from caffeine’s interaction with adenosine receptors and coffee’s polyphenol content, which may reduce harmful protein accumulation associated with Alzheimer’s disease.
Yet Johnson remains unmoved. “Even with these benefits, I can’t do it; caffeine creates a physiological roller coaster and enslaves me,” he wrote on social media. For someone who maintains such precise control over his biological systems, the stimulant effects apparently disrupt his carefully balanced protocols.
